

27 **Abstract**

28 Developing Alzheimer's disease (AD) is influenced by multiple genetic variants that are involved in five major AD-
29 pathways. Per individual, these pathways may differentially contribute to the modification of the AD-risk. The
30 pathways involved in the *resilience* against AD have thus far been poorly addressed. Here, we investigated to what
31 extent each molecular mechanism associates with (i) the increased risk of AD and (ii) the *resilience* against AD until
32 extreme old age, by comparing pathway-specific polygenic risk scores (pathway-PRS). We used 29 genetic variants
33 associated with AD to develop pathway-PRS for five major pathways involved in AD. We developed an integrative
34 framework that allows multiple genes to associate with a variant, and multiple pathways to associate with a gene. We
35 studied pathway-PRS in the Amsterdam Dementia Cohort of well-phenotyped AD patients (N=1,895), Dutch
36 population controls from the Longitudinal Aging Study Amsterdam (N=1,654) and our unique 100-plus Study cohort
37 of cognitively healthy centenarians who avoided AD (N=293). Last, we estimated the contribution of each pathway to
38 the genetic risk of AD in the general population. All pathway-PRS significantly associated with increased AD-risk and
39 (in the opposite direction) with resilience against AD (except for *angiogenesis*, $p < 0.05$). The pathway that contributed
40 most to the overall modulation of AD-risk was β -amyloid metabolism (29.6%), which was driven mainly by *APOE*-
41 variants. After excluding *APOE* variants, all pathway-PRS associated with increased AD-risk (except for *angiogenesis*,
42 $p < 0.05$), while specifically *immune response* ($p = 0.003$) and *endocytosis* ($p = 0.0003$) associated with resilience against AD.
43 Indeed, the variants in these latter two pathways became the main contributors to the overall modulation of genetic
44 risk of AD (45.5% and 19.2%, respectively). The genetic variants associated with the resilience against AD indicate
45 which pathways are involved with maintained cognitive functioning until extreme ages. Our work suggests that a
46 favorable immune response and a maintained endocytosis pathway might be involved in general neuro-protection,
47 which highlight the need to investigate these pathways, next to β -amyloid metabolism.

48

49 Introduction

50 Due to changes in lifestyle and advances in healthcare, life expectancy has greatly increased during the last century.[1]
51 A consequence of an increased fraction of aged individuals in the population is the increased prevalence of age-related
52 diseases. A major contribution to poor health and disability at old age is cognitive decline due to Alzheimer's disease
53 (AD).[2] The incidence of AD increases exponentially with age and reaches ~40% per year at 100 years, making it one
54 of the most prevalent diseases in the elderly.[3] Yet, a small proportion of the population (<0.1%) avoids the disease,
55 reaching at least 100 years while maintaining a high level of cognitive health.[4]

56

57 Both the development and the resilience against AD are determined by a combination of beneficial and harmful
58 environmental and genetic factors that is unique for each individual.[1, 5, 6] Thus far, large collaborative genome-wide
59 association studies (GWAS) have discovered common genetic variants associated with a small modification of the risk
60 of AD.[7–20] Of these, the alleles that encompass the *APOE* gene explain the largest proportion of the risk to develop
61 or the chance to escape AD. We previously showed that those who avoided cognitive decline until extreme ages
62 (cognitively healthy centenarians) were relatively depleted with genetic variants associated with an increased risk of
63 AD.[21] However, the degree of depletion of these variants in the genomes of cognitively healthy centenarians relative
64 to the middle-aged healthy individuals was not constant, which might point towards a differential impact of associated
65 biological pathways on either avoiding or developing AD. This led us to hypothesize that an individuals' chance to
66 develop AD or to being resilient against AD may be determined by pathway-specific risk.

67

68 Previous studies indicated that five specific biological pathways associate strongly with AD risk: *immune response*, *β -*
69 *amyloid metabolism*, *cholesterol/lipid dysfunction*, *endocytosis* and *angiogenesis*.^[22–27] However, the extent to which
70 different pathways contribute to the polygenic risk of AD is unknown. The degree to which a pathway contributes to
71 the individual risk can be studied with pathway-specific polygenic risk scores (PRS).^[28, 29] In a typical polygenic risk
72 score, the effect-sizes of all genetic variants that significantly associate with a trait are combined.^[30] In a pathway-
73 specific PRS, additional information is necessary: (i) the association of genetic variants to genes, and (ii) the association
74 of genes to pathways. Previous studies of pathway-PRS in AD approached these challenges using the closest gene for
75 variant mapping. For this, a 1:1 relationship between variants and genes is assumed, however, as AD-associated
76 variants are mostly intronic or intergenic, the closest gene is not necessarily the gene affected by the variant.
77 Additionally, different databases often have different functional annotations of genes, and this uncertainty was
78 previously not taken into account when constructing pathway-PRS.^[28, 29]

79

80 An accurate mapping of the genetic risk of AD conferred by specific molecular pathways may lead to a greater
81 comprehension of individual AD subtypes and might represent a first important step for the development of targeted
82 intervention strategies and personalized medicine.[31] Here, we propose a novel integrative framework to construct
83 pathway-PRS for the five major pathways suggested to be involved in AD. We then tested whether specific pathways
84 differentially contributed to the risk of AD as well as to the chance of avoiding AD until extreme old ages. Finally, we
85 estimated the contribution of each pathway to the polygenic risk of AD in the general (healthy middle-aged)
86 population.

87

88 **Methods**

89 **Populations**

90 Population subjects are denoted by *P*: they consist of a representative Dutch sample of 1,779 individuals aged 55-85
91 years from the Longitudinal Aging Study Amsterdam (LASA).[32, 33] Patients diagnosed with AD are denoted by *A*.
92 The patients are either clinically diagnosed probable AD patients from the Amsterdam Dementia Cohort (N=1,630) or
93 pathologically confirmed AD patients from the Netherlands Brain Bank (N=436).[34–36] Escapers of AD are denoted
94 by *C*: these are 302 cognitively healthy centenarians from the 100-plus Study cohort. This study includes individuals
95 who can provide official evidence for being aged 100 years or older and self-report to be cognitively healthy, which is
96 confirmed by a proxy.[4] All participants and/or their legal representatives provided written informed consent for
97 participation in clinical and genetic studies. The Medical Ethics Committee of the Amsterdam UMC (METC)
98 approved all studies.

99

100 **Genotyping and imputation**

101 We selected 29 common genetic variants (minor allele frequency >1%) for which a genome-wide significant association
102 with clinically identified AD cases was found (*Table S1*).[7–18, 37–40] We genotyped all individuals using Illumina
103 Global Screening Array (GSAsharedCUSTOM_20018389_A2) and applied established quality control measures.[41]
104 Briefly, we used high-quality genotyping in all individuals (individual call rate >98%, variant call rate >98%) and
105 Hardy–Weinberg equilibrium-departure was considered significant at $p < 1 \times 10^{-6}$. Genotypes were prepared for
106 imputation using provided scripts (HRC-1000G-check-bim.pl).[42] This script compares variant ID, strand and allele
107 frequencies to the haplotype reference panel (HRC v1.1, April 2016).[35] Finally, all autosomal variants were submitted
108 to the Michigan imputation server (<https://imputationserver.sph.umich.edu>). The server uses SHAPEIT2 (v2.r790) to
109 phase data and imputation to the reference panel (v1.1) was performed with Minimac3. Variant-genotypes of total of
110 1,779 population subjects, 302 centenarians and 2,052 AD cases passed quality control. Prior to analysis, we excluded

111 individuals of non-European ancestry ($N_C = 2$, $N_P = 63$ and $N_A = 94$ based on 1000Genomes clustering)[43] and
112 individuals with a family relation ($N_C = 7$, $N_P = 62$ and $N_A = 63$, identity-by-descent >0.3), leaving 1,654 population
113 subjects, 293 cognitively healthy centenarians and 1,895 AD cases for the analyses.

114

115 Polygenic risk score

116 To calculate the personal polygenic risk scores, or the genetic risk of AD that affects a single individual, the effect-
117 sizes of all genetic variants that significantly associate with AD are combined. Formally, a PRS is defined as the sum
118 of trait-associated alleles carried by an individual across a defined set of genetic loci, weighted by effect-sizes estimated
119 from a GWAS.[30] We constructed a polygenic risk score (PRS) using 29 variants that were previously associated with
120 AD. As weights for the PRS, we used the variant effect-sizes (log of odds ratio) as published in large GWAS of AD
121 (Table S1). Given a subject s , the PRS is defined as:

$$122 \quad PRS^s = \sum_k^K (dos_k^s * \beta_k) \quad (i)$$

123 where K is the full set of variants, dos_k^s is the allele dosage from the (imputed) genotype of variant k in subject s and
124 β_k is the effect size as determined in the largest published AD case-control GWAS (Table S1).

125

126 Mapping variants to pathways

127 We studied the five pathways implicated in AD: *immune response*, *β -amyloid metabolism*, *cholesterol/lipid dysfunction*,
128 *endocytosis* and *angiogenesis*. [22–25, 44, 45] For these pathways we developed the *variant-pathway mapping* M_p^k , which
129 represents the degree of involvement of a given variant in the pre-selected pathways. To generate this value, we (i)
130 associated genetic variants to genes (*variant-gene mapping*), (ii) associated genes to pathways (*gene-pathway mapping*)
131 and (iii) combined these mappings in the *variant-pathway mapping*.

132

133 *Variant-gene mapping*: the association of a variant with a specific gene is not straight-forward as the closest gene is not
134 necessarily the gene affected by the variant. The two most recent and largest GWAS of AD addressed the relationship
135 between genetic variants and associated genes applying two independent methods.[19, 20] Briefly, one study used (i)
136 gene-based annotation, (ii) expression-quantitative trait loci (eQTL) analyses, (iii) gene cluster/pathway analyses, and
137 (iv) differential gene expression analysis between AD cases and healthy controls.[19] The other study integrated (i)
138 positional mapping, (ii) eQTL gene-mapping, and (iii) chromatin interaction as implemented in the tool Functional
139 Mapping and Annotation of Genome-Wide Association Studies (FUMA).[20, 46] The list of genes most likely affected
140 by each variant was obtained from both studies and used to derive a weighted mapping for each genetic variant k to
141 one or more genes g , m_g^k , denoted as the *variant-gene mapping* weight. This weight was calculated by counting the

142 number of times a variant k was associated with gene g across the two studies and dividing this by the total number of
143 genes associated with the variant (*Table S2*). For variants in/near *CR1*, *PILRA*, *PLCG2*, *ABCA7* and *APOE*, we assumed
144 the culprit gene as known, and we assigned a 1:1 relationship between the variant and the gene (*Table S2*).

145

146 *Gene-pathway mapping*: each gene from the *variant-gene mapping* was classified into the pre-defined set of pathways
147 integrating four sources of information:

- 148 1. Gene-sets from the unsupervised pathway enrichment analysis within MAGMA statistical framework from
149 *Kunkle et al.*, [19] in which the authors identified 9 significant pathways (coupled with the genes involved in
150 each pathway), which we mapped to 3 of the 5 pathways of interest (*Table S3*);
- 151 2. Associated genes from Gene-ontology (GO, from *AmiGO 2* version 2.5.12, released on 2018-04) terms
152 resembling the 5 pathways of interest within the biological processes tree (including all child-terms) (*Table*
153 *S4*); [47, 48]
- 154 3. Gene-sets derived from an unsupervised functional clustering analysis within DAVID (v6.8, released on 2016-
155 10); [49, 50] the gene-set from the *variant-gene mapping* was used to obtain 12 functional clusters which were
156 then mapped to the 5 pre-selected pathways using a set of keywords (*Table S5* and *Table S6*);
- 157 4. Gene-pathway associations from a recent review concerning the genetic landscape of AD (*Table S7*); [22]

158 By counting the number of times each gene was associated to each pathway according to these sources, and dividing
159 by the total number of associations per gene, we obtained a weighted mapping of each gene g to one or more pathways
160 p , w_p^g , denoted as the *gene-pathway mapping weight* (*Table S8* and *Table S9*). In case the *gene-pathway mapping* could
161 not be calculated (*i.e.* there was no mapping to any of the pathways of consideration), we excluded the gene from
162 further analyses (*Table S8* and *Table S9*).

163

164 To associate variants with pathways, we combined the *variant-gene mapping* and the *gene-pathway mapping*. Given a
165 variant k , mapping to a set of genes G , and a pathway p , we define the weight of the variant to the pathway (M_p^k) as:

$$166 \quad M_p^k = \sum_g^G (m_g^k * w_p^g) \quad (2)$$

167 where m_g^k is the *variant-gene mapping weight* of variant k to gene g , and w_p^g is the *gene-pathway mapping weight* of gene
168 g to pathway p . In this way, for each variant, we calculated a score indicative of the involvement of the variant in each
169 of the five pathways (*variant-pathway mapping*, *Table S10*). For some variants no *variant-pathway mapping* was possible.
170 We marked these variants as unmapped (*Table S10*).

171

172 **Pathway-specific polygenic risk score**

173 For the pathway-specific polygenic risk score (pPRS), we extended the definition of the PRS by adding as
174 multiplicative factor the *variant-pathway mapping* weight of each variant. Given a sample s and a pathway p , we defined
175 the pPRS as:

$$176 \quad pPRS_p^s = \sum_k^K (dos_k^s * \beta_k * M_k^p) \quad (3)$$

177 where M_k^p is the *variant-pathway mapping* of variant k to pathway p .

178

179 Association of PRSs in the three cohorts

180 We calculated the polygenic risk score (PRS) and pathway-PRS (pPRS) for the population subjects, the AD cases and
181 the cognitively healthy centenarians (P , A and C , respectively). Prior to analyses, the PRSs of all three populations
182 were combined together and were scaled (mean=0, SD=1). We then investigated the influence of *APOE*, gender and
183 age on the risk scores: we calculated the PRSs and pPRSs with and without the two *APOE* variants and we correlated
184 the resulting (p)PRSs with sex, age (age at inclusion for controls, age at onset for cases) and population substructure
185 components. To inspect the differential contributions of the risk scores to AD development or resilience against AD,
186 we calculated (i) the association of the risk scores (PRS and pPRS) with AD status by comparing AD cases and
187 population subjects (A vs. P), and (ii) the association of the risk scores with resilience against AD by comparing
188 cognitively healthy centenarians and population subjects (C vs. P comparison). For the associations, we used logistic
189 regression models with the PRS and pPRS as predictors, adjusting for population substructure (principal components
190 1-5). Resulting effect-sizes (log of odds ratio) can be interpreted as the odds ratio difference per one standard deviation
191 (SD) increase in the PRS, with a corresponding estimated 95% confidence intervals (95% CI). Association analyses of
192 the (p)PRS in the three population were also stratified by sex. Last, we verified the classification performances of the
193 single variants as well as the (p)PRS by calculating the area under the ROC curve for classification of AD and resilience
194 against AD.

195

196 Comparison of effect-size between *resilience* against AD and increased AD-risk

197 To further investigate the relationship between the effect of each pathway on AD and on resilience against AD, we
198 calculated the *change* in effect-size. This corresponds to the ratio between the effect-size of the association with
199 resilience against AD (log of odds ratios of C vs. P comparison) and the effect-size of the association with AD (log of
200 odds ratios of A vs. P comparison). We calculated the *change* in effect-size for the pPRS including and excluding *APOE*
201 variants. We estimated 95% confidence intervals for the effect-size ratios by sampling, and we tested for significant
202 difference between the *change* in effect-size including and excluding *APOE* variants (respectively for each of pPRS)
203 using t-test. A value for the *change* in effect-size of 1 indicates a similar effect on increased risk of AD and resilience

204 against AD. Although a value for the *change* in effect size unknown *a priori*, since all variants considered are selected
205 to be associated with AD, a value <1 is expected (*i.e.* a larger effect on AD than on resilience against AD).

206

207 Contribution of each pathway to polygenic risk of AD

208 We estimated the contribution of each pathway to the genetic risk of AD in the general population: this equals to the
209 variance explained by each of the pre-selected pathways to the genetic risk of AD. Mathematically, this is the ratio
210 between the variance of each pathway-PRS and the variance of the combined PRS as calculated in the individuals in
211 the general population. As such, it is a function of the *variant-pathway mapping*, the effect-size (log of odds ratio) of the
212 variants, and the variant frequencies. Given a variant k and the relative *variant-pathway mapping* M_k^p , we define the
213 percentage of the risk explained by each pathway p as:

$$214 \quad P^p = \frac{\sum_k^K (M_k^p * \beta_k^2 * MAF_k * (1 - MAF_k))}{\sum_k^K (\beta_k^2 * MAF_k * (1 - MAF_k))} \quad (4)$$

215 where β_k is the variant effect-size from literature, and $MAF_k * (1 - MAF_k)$ is the variance of a Bernoulli random
216 variable that occurs with probability MAF_k , *i.e.* the minor allele frequency of each variant k in our cohort of population
217 subjects. Here, M_k^p is interpreted as the probability that variant k belongs to pathway p . Importantly, for each variant,
218 $\sum_p M_k^p = 1$, so that each variant contributes equally, yet differentially at the level of each pathway. This means that
219 the variance of a variant is only counted once, even if the variant contributes to multiple pathways. When calculating
220 the contributions of each pathway, we also considered variants with missing *variant-pathway mapping*. For these
221 variants, the *variant-pathway mapping* was set to 1 for an *unmapped* pathway. Together, the pathway PRS variances sum
222 to the total PRS variance.

223

224 Implementation

225 We performed quality control of genotype data as well as population stratification analysis and relatedness analysis
226 with PLINK (v2.0). All subsequent analyses were performed with R (v3.5.2), Bash and Python (v2.7.14) scripts. We
227 provide a R script to construct pPRS and PRS using our *variant-pathway annotation* and user's genotypes. In addition,
228 all the scripts we used to perform the analyses can be found at <https://github.com/TesiNicco/pathway-PRS>.

229

230 Results

231 After quality control of the genetic data, we included 1,654 population subjects (with mean age at inclusion 62.7 ± 6.4 ,
232 53.2% females), 1,895 AD cases (with mean age at onset 69.2 ± 9.9 , 56.4% females), and 293 cognitively healthy
233 centenarians (with mean age at inclusion 101.4 ± 1.3 , 72.6% females) (P , A and C respectively).

234

235 Polygenic risk scores associate with AD and escape from AD

236 To each subject, we assigned a PRS representative of all 29 AD-associated variants, including and excluding *APOE*
237 variants. We found that the PRS, when including *APOE* variants, significantly associated with an increased risk of AD
238 and, in the opposite direction, with increased chance of resilience against AD (*A vs. P: OR=2.61, 95% CI=[2.40-2.83],*
239 *p=8.4x10⁻¹¹³* and *C vs. P: OR=0.54, 95% CI=[0.45-0.65], p=1.1x10⁻¹⁰*) (*Figure 1A* and *Table S11*). When excluding *APOE*
240 variants, the PRS was still significantly associated with an increased risk of AD and, in the opposite direction, with
241 increased risk of resilience against AD (*A vs. P: OR=1.30, 95% CI=[1.22-1.40], p=3.1x10⁻¹⁴* and *C vs. P: OR=0.78, 95% CI=[0.69-*
242 *0.89], p=2.4x10⁻⁴*) (*Figure 1B*, and *Table S11*).

243

244 Pathway-specific PRS associate with AD and escape from AD

245 We annotated the 29 AD-associated genetic variants to 5 selected pathways (*Figure 2*). According to our *variant-gene*
246 *mapping*, the 29 AD-associated variants mapped to 110 genes (*Table S8*). The number of genes associated with each
247 variant ranged from 1 (*e.g.* for variants in/near *CRI, PILRA, SORL1, ABCA7, APOE* or *PLCG2*), to 30 (a variant in the gene-
248 dense region within the *HLA* region) (*Figure 2* and *Table S8*). We were able to calculate the *gene-pathway mapping*
249 weight for 69 genes (*Table S9*). The remaining 41 genes were not mapped to the 5 pathways. In total, we calculated the
250 *variant-pathway mapping* for 23 loci to at least one of the pre-selected biological pathways (*Figure 2* and *Table S10*).

251

252 We then calculated the pPRS for each pathway in population subjects, AD cases and cognitively healthy centenarians
253 including and excluding *APOE* variants (*Figure 1B* and *1C*). The number of variants that contributed to each pPRS was
254 19 for *immune response*, 11 for *β-amyloid metabolism*, 19 for *endocytosis*, 8 for *cholesterol/lipid dysfunction* and 4 for
255 *angiogenesis* pathways (*Table S10* and *Table S11*). Overall, the pPRS (including and excluding the *APOE* variants)
256 positively and significantly correlated with each other and with the overall PRS (*Figure S1*), and did not correlate with
257 gender and age (*Figure S1*).

258

259 When including *APOE* variants, the pPRSs of all pathways (except for *angiogenesis*) significantly associated with
260 increased risk of AD, independently from gender (*A vs. P, immune response: OR=2.15, 95% CI=[1.99-2.32], p=2.0x10⁻⁸⁰; β-*
261 *amyloid metabolism: OR=2.52, 95% CI=[2.32-2.73], p=7.8x10⁻¹⁰⁹; endocytosis: OR=2.55, 95% CI=[2.35-2.77], p=1.7x10⁻¹⁰⁹;*
262 *cholesterol/lipid dysfunction: OR=2.55, 95% CI=[2.35-2.76], p=2.1x10⁻¹¹⁰; angiogenesis: OR=1.05, 95% CI=[0.98-1.12], p=0.134)*
263 (*Figure 1B, Table S11, Figure S2* and *Table S12*). The association of pPRSs with increased chance of being resilient against
264 AD was in the opposite direction for all pathways, and the association was significant for all pathways except for

265 *angiogenesis* (*C vs. P*, *immune response*: $OR=0.64$, 95% $CI=[0.54-0.74]$, $p=1.4 \times 10^{-8}$; β -*amyloid metabolism*: $OR=0.59$, 95%
266 $CI=[0.49-0.71]$, $p=2.7 \times 10^{-8}$; *endocytosis*: $OR=0.55$, 95% $CI=[0.46-0.66]$, $p=1.3 \times 10^{-10}$; *cholesterol/lipid dysfunction*: $OR=0.58$, 95%
267 $CI=[0.48-0.70]$, $p=1.8 \times 10^{-8}$; *angiogenesis*: $OR=0.90$, 95% $CI=[0.79-1.01]$, $p=0.078$) (Figure 1B, Table S11). Directions of effects
268 were consistent in both males and females, but the significance of associations was reduced due to stratification (Table
269 S12 and Figure S2).

270
271 When excluding *APOE* variants, the pPRSs of all pathways (except for the *angiogenesis*) was still significantly associated
272 with increased risk of AD without specific gender effects (*A vs. P*, *immune response*: $OR=1.19$, 95% $CI=[1.11-1.27]$, $p=5.5 \times 10^{-7}$;
273 β -*amyloid metabolism*: $OR=1.19$, 95% $CI=[1.12-1.28]$, $p=2.0 \times 10^{-7}$; *endocytosis*: $OR=1.27$, 95% $CI=[1.19-1.36]$, $p=2.8 \times 10^{-12}$;
274 *cholesterol/lipid dysfunction*: $OR=1.18$, 95% $CI=[1.11-1.27]$, $p=7.5 \times 10^{-7}$; *angiogenesis*: $OR=1.05$, 95% $CI=[0.98-1.12]$, $p=0.134$)
275 (Figure 1C, Table S11, Figure S2 and Table S12). The association of pPRSs with increased chance of being resilient against
276 AD was in the opposite direction for all pathways, yet the association was significant only for the *immune response* and
277 the *endocytosis* pPRS (*C vs. P*, *immune response*: $OR=0.82$, 95% $CI=[0.72-0.94]$, $p=0.003$; β -*amyloid metabolism*: $OR=0.91$,
278 95% $CI=[0.80-1.03]$, $p=0.131$; *endocytosis*: $OR=0.79$, 95% $CI=[0.70-0.90]$, $p=2.8 \times 10^{-4}$; *cholesterol/lipid dysfunction*: $OR=0.91$,
279 95% $CI=[0.80-1.03]$, $p=0.145$; *angiogenesis*: $OR=0.90$, 95% $CI=[0.79-1.01]$, $p=0.078$) (Figure 1C and Table S11).

280 In the sex-stratified analysis, females reported consistent direction of effects and significant associations of *immune*
281 *response* and *endocytosis* pathways, while in males the direction was consistent for *immune response*, *endocytosis* and
282 *angiogenesis* pathways, and it was opposite for β -*amyloid metabolism* and *cholesterol/lipid dysfunction* (yet not significant)
283 (Figure S2 and Table S12).

284 We note that apart from *APOE* variants (for which we stratified the analyses for), there was no major driver in the
285 pPRS as well as the single-variant associations (Figure S3 and Figure S4).

286

287 Comparison of effect on AD and escaping AD

288 To further evaluate the association of the pPRSs with AD and with resilience against AD, we compared, for each pPRS,
289 the reciprocal effect size associated with resilience against AD with the effect size associated with increased risk of AD
290 (*change in effect size*, Figure 3A). When including *APOE* variants, the *change in effect-size* was <1 for all pathways (except
291 for the *angiogenesis* pathway) (Figure 3B). This is expected as the effect-size of *APOE* variants on *causing* AD is much
292 larger than its effect on resilience against AD (Figure 3A). When excluding *APOE* variants, the *change in effect-size* was
293 still <1 for β -*amyloid metabolism* and *cholesterol/lipid metabolism* (respectively 0.54 and 0.58), but it approximated 1 for
294 *endocytosis* (0.96) and it was larger than 1 for the *immune response* and *angiogenesis* (respectively 1.12 and 2.15) (Figure 3B).
295 Interestingly, we found that the relative effect-size for *immune response* and *endocytosis* excluding *APOE* variants was

296 significantly higher than that including *APOE* variants ($p < 2.1 \times 10^{-197}$ and $p < 8.9 \times 10^{-180}$ respectively), suggesting a larger
297 effect on resilience against AD compared to AD-risk for these pathways, specifically when excluding *APOE* variants
298 (Figure 3B).

299

300 Contributions of each pathway to the polygenic risk of AD

301 Finally, we estimated the relative contribution of each pathway to the polygenic risk of AD in the general population.
302 This is indicative of the degree of involvement of each pathway to the total polygenic risk of AD, and as such it is based
303 on our *variant-pathway mapping*. Including *APOE* variants, the contribution of the pathways to the total polygenic risk
304 of AD was 29.6% for β -amyloid metabolism, 26.6% for immune response, 21.6% for endocytosis, 19.5% for cholesterol/lipid
305 dysfunction, 0.3% for angiogenesis and 2.3% for the unmapped variants (Figure 4A).

306 When we excluded *APOE* variants, the contribution of the pathways to the total polygenic risk of AD was 45.5% for
307 immune response, 19.2% for endocytosis, 13.7% for β -amyloid metabolism, 8% for cholesterol/lipid dysfunction, 1.4% for
308 angiogenesis and 12.3% for the unmapped variants (Figure 4B).

309

310 Discussion

311 In this work, we studied 29 common genetic variants known to associate with AD using polygenic risk scores and
312 pathway-specific polygenic risk scores. As expected, we found that a higher PRS for AD was associated with a higher
313 risk of AD. Previous studies showed that polygenic risk score of AD not only associated with increased risk of AD, but
314 also with neuropathological hallmarks of AD, lifetime risk and the age at onset in both *APOE* $\epsilon 4$ carriers and non-
315 carriers.[28, 29, 51–55] We now add that, using our unique cohort of cognitively healthy centenarians, the PRS for AD
316 also associates with resilience against AD at extremely old ages. This adds further importance to the potentiality of
317 using PRS and *APOE* genotype in a clinical setting.[51, 52, 54, 56] In addition, our analyses suggest that the long-term
318 preservation of cognitive health is associated with the selective survival of individuals with the lowest burden of risk-
319 increasing variants or, vice versa, the highest burden of protective variants.

320 Using an innovative approach, we studied five pathways previously found to be involved in AD as well as the
321 contribution of these pathways to the polygenic risk of AD. We showed that all pathways-PRS except *angiogenesis*
322 associate with increased AD risk, both including and excluding *APOE* variants and independently from gender. When
323 we studied the association of pathways-PRS with resilience against AD until extreme old ages, we found that, as
324 expected, the enrichment of the protective *APOE* $\epsilon 2$ allele and the depletion of the risk-increasing *APOE* $\epsilon 4$ allele
325 represented a major factor in avoiding AD. However, when excluding the two *APOE* variants, only *immune response*
326 and *endocytosis* significantly associated with an increased chance to be resilient against AD. Interestingly, both

327 pathways had a larger or similar effect on resilience against AD-resilience compared to developing AD, suggesting
328 that these pathways might be involved in general neuro-protective functions. Based on the variant effect size, variant
329 frequency and our *variant-pathway mapping*, we found that the β -amyloid metabolism (29.6%) followed by immune
330 response (26.6%) were the major contributors to general modification of AD-risk. After excluding *APOE* variants,
331 according to our analysis, immune response (45.5%) and endocytosis (19.2%) contributed most to the modification of AD-
332 risk.

333

334 Our approach to map variants to associated genes and to map genes to pathways resulted in a weighted annotation of
335 variants to pathways that allowed for uncertainty in gene as well as pathway assignment, which was not done
336 previously. We note that considering uncertainty in variant-gene as well as gene-pathway assignments is crucial
337 because most genetic variants are in non-coding regions, which makes the closest gene not necessarily the culprit
338 gene, and because different functional annotation-sources often do not overlap. In our *variant-pathway mapping*, a
339 larger number of annotations (both variant-genes and gene-pathways), generally causes a dilution of the “true” variant
340 effect, reflecting increasing uncertainty in the annotation sources used. This depends on the specific regions, for
341 example, the HLA region carries many genes with large linkage signals, however, all genes in this region are typically
342 annotated with immune response. We point out that the power of the PRSs does not only reflect the effect-size of the
343 variants, but also the number and frequency of the variants that contribute to the PRSs: due to this, a larger number
344 of very common variants with relatively small effect-size can still have more power (yet small ORs) than a small
345 number of relatively rare variants with high effect-size. The pathway-specific PRS that we proposed in this manuscript
346 can be re-used for the identification of subtypes of AD patients compromised in a specific AD-associated pathway.
347 This is of interest for clinical trials, in order to test responsiveness to compounds in specific subsets of patients. For
348 example, monoclonal antibody targeting *TREM2* receptors could work better in AD patients who have an impaired
349 immune response pathway. Recently, several studies attempted to construct pathway-specific PRS to find
350 heterogeneity in AD patients based on a genetic basis.[28, 29] In line with our findings, *Ahmad et al.* found that genes
351 capturing endocytosis pathway significantly associated with AD and with the conversion to AD.[29] Other studies used
352 less variants [28] or less stringent selection for variants, and did not observe a differential involvement of pathways in
353 AD etiology.[57]

354

355 The amyloid cascade hypothesis has been dominating AD-related research in the last two decades. However,
356 treatments targeting amyloid have, so far, not been able to slow or stop disease progression. This has led to an
357 increased interest for the other pathways that are important in AD pathogenesis.[22] Part of the current view of the
358 etiology of AD is that the dysregulation of the immune response is a major causal pathway, and that AD is not only a

359 consequence of β -amyloid metabolism.[58, 59] In addition, previous studies showed that healthy immune and
360 metabolic systems are associated with longer and healthier lifespan.[1, 60] Our results indicate that, excluding *APOE*
361 variants, the effect of immune response and endocytosis on escaping AD is stronger or comparable to the effect on
362 causing AD. This suggests that these pathways might be involved in the maintenance of general cognitive health, as
363 the cognitively healthy centenarians represent the escape of all neurodegenerative diseases until extreme ages. We
364 recently found evidence for this hypothesis in the protective low frequency variant in *PLCG2*, which is involved in the
365 regulation of the immune response.[53] This variant is enriched in cognitively healthy centenarians, and protects
366 against AD as well as frontotemporal dementia and dementia with Lewy bodies.[53] We included this variant in the
367 total PRS as well as in the pathway-PRS for the immune response (*variant-pathway mapping* was 60%) and endocytosis
368 (*variant-pathway mapping* was 40%). Regarding endocytosis, this pathway is thought to play a role both in neurons, as
369 part of the β -amyloid metabolism, but also in glia cells, as part of the immune response. Thus, a dysregulation in the
370 interplay between these pathways might lead to an imbalance of immune signaling factors, favoring the engulfment
371 of synapses and AD-associated processes. This, in turn, may contribute to the accumulation of amyloid and tau
372 pathologies.[61–64].

373

374 We assessed the effect of common and low frequency variants on the development and the escape of AD. Therefore,
375 the contributions of rare, causative variants associated with increased AD risk, such as those in *APP*, *PSEN1*, *PSEN2*,
376 *TREM2* and *SORL1* were not considered. Despite the large odds ratios to develop AD associated with carrying such
377 variants, the frequency of these variants in the population is ultra-low, and therefore have a minor effect on the total
378 AD risk in the population.[11, 12] However, future versions of the PRS will most likely include the effect of carrying
379 disease-associated rare variants. This will affect individual PRS scores and the necessity to accordingly adapt the
380 results generated with current PRSs. Compared to the sizes of recent GWAS of AD, we included relatively small
381 sample sizes, particularly with respect to the cognitively healthy centenarians, a very rare phenotype in the population
382 (<0.1%).[4] These sample sizes are however sufficient to study PRSs. The cohorts that we used in this study were not
383 used in any GWAS of AD, therefore we provide independent replication of AD PRS in a homogeneous group of
384 (Dutch) individuals.

385

386 We note that, apart from *APOE* variants (for which we stratify the analyses for), none of the other variants have been
387 associated with longevity or well cognitive functioning in the largest and most recent GWAS.[65, 66] We acknowledge
388 that our *variant-pathway mapping* reflects the current state of imperfect knowledge at the level of AD-GWAS findings,
389 variant-gene and gene-mechanism relationships. Thus, as new variants, pathways or functional relationships will be
390 identified, the contributions and the pathway-specific PRSs will need to be recalculated. Of note: the study in which

391 the genome-wide significant association with AD of the variant in/near *KANSL1* was originally identified, reported a
392 larger effect size compared to the effect size used in our manuscript, ($\beta=0.31$ and $\beta=0.07$, respectively), possibly because
393 the original analysis was stratified by *APOE*. We cannot exclude that we underestimated the contribution of *KANSL1*
394 in the analyses. Moreover, since the *KANSL1* variant did not map into one of the analyzed pathways, it was not
395 included in any of the pathway-specific PRS calculations. A limitation, not exclusive to our work, is the highly debated
396 role of *APOE* gene. We mapped the effect of *APOE* to four pathways and we are aware this assignment is relatively
397 arbitrary. We add that *APOE* has well-studied (cardio)vascular properties that are included in our cholesterol and lipid
398 metabolism pathway. The combination of a large effect and unclear pathway assignment makes that pathway-PRS
399 including *APOE* challenging to use. Lastly, we point out that the variance contributions might change in different
400 populations, as it depends on variant frequency and population heterogeneity.

401

402 Concluding, with the exclusion of *APOE* variants and based on our functional annotation of variants, the aggregate
403 contribution of the immune response and endocytosis represents more than 60% of the currently known polygenic
404 risk of AD. This indicates that an intervention in these systems may have large potential to prevent AD and potentially
405 other related diseases and highlights the critical need to study (neuro)immune response and endocytosis, next to β -
406 amyloid metabolism.

407

408 Acknowledgements

409 The following studies and consortia have contributed to this manuscript. Amsterdam dementia cohort (ADC):
410 Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam
411 Neuroscience (www.amsterdamresearch.org). The Alzheimer Center Amsterdam is supported by Stichting Alzheimer
412 Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting
413 Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European
414 Alzheimer DNA biobank) funded by the JPCo-fuND FP-829-029 (ZonMW projectnumber 733051061). 100-plus study:
415 we are grateful for the collaborative efforts of all participating centenarians and their family members and/or relatives.
416 This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Dioraphte, horstingstuit
417 foundation, Memorabel (ZonMW projectnumber 733050814) and Stichting VUmc Fonds. Genotyping of the 100-plus
418 study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPCo-fuND FP-829-
419 029 (ZonMW projectnumber 733051061). The clinical database structure was developed with funding from Stichting
420 Dioraphte. Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands
421 Ministry of Health, Welfare and Sports, Directorate of Long-Term Care. The authors are grateful to all LASA

422 participants, the fieldwork team and all researchers for their ongoing commitment to the study. This work was in part
423 carried out on the Dutch national e-infrastructure with the support of SURF Cooperative. The authors declare no
424 conflict of interests.


425

426 References

- 427 1. Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. *Nature*. 2018;561:45–56.
- 428 2. 2012 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2012;8:131–168.
- 429 3. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age
430 in the oldest old: The 90+ study. *Ann Neurol*. 2010;67:114–121.
- 431 4. Holstege H et al. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. *Eur J*
432 *Epidemiol*. 2018. 25 October 2018. <https://doi.org/10.1007/s10654-018-0451-3>.
- 433 5. Niccoli T, Partridge L. Ageing as a Risk Factor for Disease. *Curr Biol*. 2012;22:R741–R752.
- 434 6. Brooks-Wilson AR. Genetics of healthy aging and longevity. *Hum Genet*. 2013;132:1323–1338.
- 435 7. Lambert JC et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat*
436 *Genet*. 2013;45:1452–1458.
- 437 8. Harold D et al. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with Alzheimer's
438 disease. *Nat Genet*. 2009;41:1088–1093.
- 439 9. Seshadri S et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. *JAMA*. 2010;303:1832–1840.
- 440 10. Desikan RS et al. Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. *Circulation*.
441 2015;131:2061–2069.
- 442 11. Sims R et al. Rare coding variants in *PLCG2*, *ABI3*, and *TREM2* implicate microglial-mediated innate immunity in
443 Alzheimer's disease. *Nat Genet*. 2017;49:1373–1384.
- 444 12. Guerreiro R et al. *TREM2* variants in Alzheimer's disease. *N Engl J Med*. 2013;368:117–127.
- 445 13. Jonsson T et al. Variant of *TREM2* associated with the risk of Alzheimer's disease. *N Engl J Med*. 2013;368:107–116.
- 446 14. Hollingworth P et al. Common variants at *ABCA7*, *MS4A6A/MS4A4E*, *EPHA1*, *CD33* and *CD2AP* are associated with
447 Alzheimer's disease. *Nat Genet*. 2011;43:429–435.
- 448 15. Naj AC et al. Common variants at *MS4A4/MS4A6E*, *CD2AP*, *CD33* and *EPHA1* are associated with late-onset
449 Alzheimer's disease. *Nat Genet*. 2011;43:436–441.
- 450 16. Jun G et al. A novel Alzheimer disease locus located near the gene encoding tau protein. *Mol Psychiatry*. 2016;21:108–117.
- 451 17. Steinberg S et al. Loss-of-function variants in *ABCA7* confer risk of Alzheimer's disease. *Nat Genet*. 2015;47:445–447.
- 452 18. Marioni R et al. GWAS on family history of Alzheimer's disease. 2018.
- 453 19. Alzheimer Disease Genetics Consortium (ADGC), et al. Genetic meta-analysis of diagnosed Alzheimer's disease
454 identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet*. 2019;51:414–430.
- 455 20. Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's
456 disease risk. *Nat Genet*. 2019;51:404–413.
- 457 21. Tesi N et al. Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme
458 control analysis of Alzheimer's disease. *Eur J Hum Genet*. 2018. 26 September 2018. <https://doi.org/10.1038/s41431-018-0273-5>.
- 459 22. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical
460 implications and perspectives. *Genet Med*. 2016;18:421–430.
- 461 23. Hardy J et al. Pathways to Alzheimer's disease. *J Intern Med*. 2014;275:296–303.
- 462 24. Naj AC, Schellenberg GD, for the Alzheimer's Disease Genetics Consortium (ADGC). Genomic variants, genes, and
463 pathways of Alzheimer's disease: An overview. *Am J Med Genet B Neuropsychiatr Genet*. 2017;174:5–26.
- 464 25. Verheijen J, Sleegers K. Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics.
465 *Trends Genet*. 2018;34:434–447.
- 466 26. Bennett RE et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic
467 mice and human Alzheimer's disease. *Proc Natl Acad Sci*. 2018;115:E1289–E1298.
- 468 27. Di Marco LY et al. Vascular dysfunction in the pathogenesis of Alzheimer's disease — A review of endothelium-
469 mediated mechanisms and ensuing vicious circles. *Neurobiol Dis*. 2015;82:593–606.
- 470 28. Darst BF et al. Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function
471 in a Sample at Increased Risk for Alzheimer's Disease. *J Alzheimers Dis*. 2016;55:473–484.

- 472 29. Ahmad S et al. Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam
473 Study. *Alzheimers Dement.* 2018;14:848–857.
- 474 30. Dudbridge F. Power and Predictive Accuracy of Polygenic Risk Scores. *PLoS Genet.* 2013;9:e1003348.
- 475 31. Freudenberg-Hua Y, Li W, Davies P. The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A
476 Narrative Review. *Front Med.* 2018;5:108.
- 477 32. Huisman M et al. Cohort Profile: The Longitudinal Aging Study Amsterdam. *Int J Epidemiol.* 2011;40:868–876.
- 478 33. Hoogendijk EO et al. The Longitudinal Aging Study Amsterdam: cohort update 2016 and major findings. *Eur J*
479 *Epidemiol.* 2016;31:927–945.
- 480 34. van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. *J Alzheimers Dis.*
481 2018;62:1091–1111.
- 482 35. van der Flier WM et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. *J Alzheimers Dis JAD.*
483 2014;41:313–327.
- 484 36. Rademaker MC, de Lange GM, Palmen SJMC. The Netherlands Brain Bank for Psychiatry. *Handb. Clin. Neurol.*, vol.
485 150, Elsevier; 2018. p. 3–16.
- 486 37. Lambert J-C et al. Genome-wide association study identifies variants at *CLU* and *CR1* associated with Alzheimer's
487 disease. *Nat Genet.* 2009;41:1094–1099.
- 488 38. Strittmatter WJ et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in
489 late-onset familial Alzheimer disease. *Proc Natl Acad Sci U S A.* 1993;90:1977–1981.
- 490 39. Corder EH et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet.*
491 1994;7:180–184.
- 492 40. Jansen I et al. Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimers disease risk. 2018.
- 493 41. Das S et al. Next-generation genotype imputation service and methods. *Nat Genet.* 2016;48:1284–1287.
- 494 42. McCarthy S et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet.* 2016;48:1279–1283.
- 495 43. 1000 Genomes Project Consortium et al. A global reference for human genetic variation. *Nature.* 2015;526:68–74.
- 496 44. Jefferies WA et al. Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease. *Alzheimers*
497 *Res Ther.* 2013;5:64.
- 498 45. Vagnucci AH, Li WW. Alzheimer's disease and angiogenesis. *The Lancet.* 2003;361:605–608.
- 499 46. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations
500 with FUMA. *Nat Commun.* 2017;8.
- 501 47. Ashburner M et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet.*
502 2000;25:25–29.
- 503 48. The Gene Ontology Consortium. Expansion of the Gene Ontology knowledgebase and resources. *Nucleic Acids Res.*
504 2017;45:D331–D338.
- 505 49. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID
506 bioinformatics resources. *Nat Protoc.* 2009;4:44–57.
- 507 50. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional
508 analysis of large gene lists. *Nucleic Acids Res.* 2009;37:1–13.
- 509 51. Escott-Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed Alzheimer
510 disease: PRS Analysis of AD. *Ann Neurol.* 2017;82:311–314.
- 511 52. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction captures nearly all common genetic
512 risk for Alzheimer's disease. *Neurobiol Aging.* 2017;49:214.e7–214.e11.
- 513 53. DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank) et al. A
514 nonsynonymous mutation in *PLCG2* reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal
515 dementia, and increases the likelihood of longevity. *Acta Neuropathol (Berl).* 2019. 27 May 2019. <https://doi.org/10.1007/s00401-019-02026-8>.
- 516 517 54. for the International Genomics of Alzheimer's Project et al. Evaluation of a Genetic Risk Score to Improve Risk


- 518 Prediction for Alzheimer's Disease. *J Alzheimers Dis.* 2016;53:921–932.
- 519 55. Chaudhury S et al. Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive
520 impairment. *Transl Psychiatry.* 2019;9.
- 521 56. van der Lee SJ et al. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and
522 dementia: a community-based cohort study. *Lancet Neurol.* 2018;17:434–444.
- 523 57. Leonenko G et al. Genetic risk for Alzheimer's disease is distinct from genetic risk for amyloid deposition. *Ann Neurol.*
524 2019. 14 June 2019. <https://doi.org/10.1002/ana.25530>.
- 525 58. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. *Science.* 2016;353:777–783.
- 526 59. Heneka MT et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* 2015;14:388–405.
- 527 60. Joshi PK et al. Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human
528 longevity. *Nat Commun.* 2017;8.
- 529 61. Srinivasan K et al. Untangling the brain's neuroinflammatory and neurodegenerative transcriptional responses. *Nat*
530 *Commun.* 2016;7.
- 531 62. Wang Y et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. *J Exp Med.*
532 2016;213:667–675.
- 533 63. Orre M et al. Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. *Neurobiol Aging.*
534 2014;35:2746–2760.
- 535 64. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. *J Cell Biol.* 2018;217:459–472.
- 536 65. Timmers PR et al. Genomics of 1 million parent lifespans implicates novel pathways and common diseases and
537 distinguishes survival chances. *ELife.* 2019;8.
- 538 66. Davies G et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive
539 function. *Nat Commun.* 2018;9.
- 540



541

542 **Figure 1: Boxplots of PRS and pPRS in the different settings.** Figure A (above) shows the PRS including all the 29
 543 known AD-associated variants, with and without *APOE* variants. As weight for the PRS, we used published variant
 544 effect-sizes (*Table S1*). Figure B (central) and Figure C (bottom) show the pPRS for each of the selected molecular
 545 pathways, including and excluding *APOE* variants, respectively. For all plots, risk scores were calculated for AD cases,
 546 population subjects and cognitively healthy centenarians. Then, risk scores were compared between (i) AD cases and
 547 population subjects (*A vs. P* comparison) and (ii) cognitively healthy centenarians and population subjects (*C vs. P*
 548 comparison). For representation, we scaled all PRS and pathway-PRS to be mean=0 and SD=1. For the comparison,
 549 we used logistic regression models with risk scores as predictors. Annotation: ***, *p-value* of association < 5×10^{-6} ; **, *p-*
 550 *value* of association < 5×10^{-4} ; *, *p-value* of association < 5×10^{-2} .

551



560

561

562

563

564

565


566

567


568

Figure 3: Change in effect-size between association with escaping AD and causing AD for the five pPRSs: figure A shows the effect-sizes (log of odds ratio) and the relative 95% confidence intervals of the association of the (p)PRS with both AD-risk and resilience against AD, grouped by pathway. In figure B, each bar represents the ratio between the effect-size of the association with escaping AD (*Resilience effect* in figure A) and with causing AD (*Risk effect* in figure A), respectively with and without *APOE* variants. Ratios larger than 1 are then indicative of larger effect-size on resilience against AD compared to AD-risk. We then compared the *change* in effect-size for each pathway when including and excluding *APOE* variants using t-tests. Annotation: ***, *p-value* of association < 5×10^{-6} ; **, *p-value* of association < 5×10^{-4} ; *, *p-value* of association < 5×10^{-2} .

APOE included



APOE excluded



569

570 **Figure 4: Explained variance of each pathway-specific PRS to polygenic risk of AD:** the pie charts represents the
571 explained variance of each pathway-specific PRS to the polygenic risk of AD, including and excluding *APOE* variants.
572 The contributions are calculated according to (i) our *variant-pathway mapping*, (ii) the effect size (log of odds ratio) of
573 each variant from literature (*Table S1*), and (iii) variant's frequency in our cohort of middle-aged healthy population
574 subjects. We also considered variants with missing *variant-pathway mapping* (*unmapped pathway*).

575